HER2/Neu/cerbB2 Antagonists

HER2/neu Receptor Antagonist

Breast Neoplasms

Gastrointestinal Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">KADCYLA (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate). Emtansine refers to the MCC-DM1 complex.</p><p>The antibody trastuzumab, is a well characterized recombinant monoclonal antibody product produced by mammalian (Chinese hamster ovary) cells, and the small molecule components (DM1 and MCC) are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody.  Ado-trastuzumab emtansine has the following chemical structure:</p><p><img alt="Chemical Structure" src="kadcyla-01.jpg"/></p><p>Note:  The bracketed structure is DM1 plus MCC which represents the emtansine component.  The n is, on average, 3.5 DM1 molecules per trastuzumab (Mab) molecule.</p><p>KADCYLA (ado-trastuzumab emtansine) is a sterile, white to off-white preservative free lyophilized powder in single-dose vials.  Each vial contains 100 mg or 160 mg ado-trastuzumab emtansine.  Following reconstitution, each single-dose vial contains ado-trastuzumab emtansine (20 mg/mL), polysorbate 20 [0.02% (w/v)], sodium succinate (10 mM), and sucrose [6% (w/v)] with a pH of 5.0.  The resulting solution containing 20 mg/mL ado-trastuzumab emtansine is administered by intravenous infusion following dilution.</p></section>

KADCYLA

ado-trastuzumab emtansine

ado-trastuzumab emtansine 100 MG Injection

ado-trastuzumab emtansine 100 MG Injection [KADCYLA]

ado-trastuzumab emtansine 160 MG Injection

ado-trastuzumab emtansine 160 MG Injection [KADCYLA]

trastuzumab

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Submit MSL Request

Pharmacy List 

How To Order Kadcyla

Reimbursement Information

Billing and Coding Guide

Coverage Authorization Request

Coverage Authorization Appeals

Letter of Medical Necessity 

Prescriber Service & Patient Consent Form 

Prescriber Service Form - Online Portal 

Patient Consent Form - English

Patient Consent Form - Spanish 

My Patient Solutions - HCP Portal (for managing service requests)

Enroll in Patient Savings Program

Genentech Prescriber Foundation Form 

Dosing and Administration Guide

Register for Kadcyla Updates

Other HCP Resources: Access

Other HCP Resources: Forms & Documents

FAQs - Financial Support HCPs

HERConnection Support Program 

About Kadcyla: HER2+ Early Breast Cancer

How Kadcyla is Thought to Work 

Kadcyla Side Effects and Tips: HER2+ Early Breast Cancer

Receiving Kadcyla: HER2+ Early Breast Cancer

Preparing for Kadcyla Infusion: HER2+ Early Breast Cancer

FAQs: HER2+ Early Breast Cancer

Discussion Guide: HER2+ Early Breast Cancer

Patient Brochure: HER2+ Early Breast Cancer

Patient Resources: HER2+ Early Breast Cancer

Independent Financial Support Programs

Kadcyla Financial Support Tool

About Kadcyla: HER2+ Metastatic Breast Cancer

Side Effects and Tips: HER2+ Metastatic Breast Cancer

Receiving Kadcyla: HER2+ Metastatic Breast Cancer

Preparing for Kadcyla Infusion: HER2+ Metastatic Breast Cancer

FAQs: HER2+ Metastatic Breast Cancer

Discussion Guide: HER2+ Metastatic Breast Cancer

Patient Brochure: HER2+ Metastatic Breast Cancer

Patient Resources: HER2+ Metastatic Breast Cancer

Instructions For Use: HER2+ Early Breast Cancer 

Instructions For Use: HER2+ Metastatic Breast Cancer